• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Low-dose atropine eyedrops no better than placebo for slowing myopia progression


A trial funded by the National Institutes of Health underscores need for more research to head off high myopia.

A bottle of eye drops with a drip coming off the tip. (Image Credit: AdobeStock/frankenphoto)

(Image Credit: AdobeStock/frankenphoto)

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for 2 years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI).

The trial (NCT03334253) aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncorrectable vision loss later in life. Results from the trial were published in JAMA Ophthalmology.1

According to the study, the results contradict results from recent trials, primarily in East Asia, which showed a benefit from 0.01% atropine in slowing myopia.

Michael F. Chiang, MD, director of the NEI, which is part of the National Institutes of Health (NIH), pointed out that the overall mixed results on low-dose atropine show us we need more research.

“Would a different dose be more effective in a US population? Would combining atropine with other strategies have a synergistic effect? Could we develop other approaches to treatment or prevention based on a better understanding of what causes myopia progression?” Chiang said in the NIH news release.

According to the news release, finding an optimal approach for preventing high (advanced) myopia is urgently needed given the escalating prevalence of myopia overall and the risk of it progressing to high myopia. The NIH release also noted that by 2030 it is anticipated that as many as 39 million people in the United States will have myopia, and that figure could grow to 44 million domestically and to 50% of the population worldwide.

In recent years, stronger concentrations of atropine eyedrops (0.5-1.0%) have long been used by pediatric eye doctors to slow myopia progression. While effective, such doses cause light sensitivity and blurry near vision while on the nightly eyedrops. Thus, there is interest in clinical studies assessing lower concentrations that have been shown to have fewer side effects.

Michael X. Repka, MD, professor of ophthalmology, Johns Hopkins University, pointed out that the absence of a treatment benefit in our U.S.-based study, compared with East Asian studies, may reflect racial differences in atropine response.

“The study enrolled fewer Asian children, whose myopia progresses more quickly, and included Black children, whose myopia progresses less quickly compared with other races,” Repka said.

For the study,1 187 children ages 5 to 12 years with low-to-moderate bilateral myopia were randomly assigned to use nightly atropine (0.01%) (125 children) or placebo (62 children) eyedrops for two years. Study participants, their parents, and the eye care providers were masked to the group assignments. Patient care was provided at 12 study center sites throughout the U.S.

According to the news release, following the treatment period, and 6 months after treatment stopped, there were no significant differences between the groups in terms of changes in degree of myopia compared with baseline. Nor were there significant differences in axial length within the two groups when compared with baseline measurements.

Katherine K. Weise, OD, a professor at University of Alabama at Birmingham, pointed out that it could be possible that a different concentration of atropine is needed for U.S. children to experience a benefits.

“Clinical researchers could evaluate new pharmaceuticals and special wavelengths of light in combination with optical strategies, like special glasses or contact lenses, to see what works in reducing the progression of myopia,” she said in the NIH news release.

The study1 also found that among children, myopia will stabilize in about half of children around age 16 years, and among an increasingly larger percentage as they get older. By their early twenties, about 10% of individuals with myopia will continue to grow more nearsighted, and by age 24 years that percentage is 4%.

“Vision scientists may help us figure out what’s different about the myopic eye, even among different races and ethnicities, to help create new treatment strategies,” Weise said in the NIH news release. “It will take a real convergence of eye research to solve the environmental, genetic, and structural mystery of myopia.”

According to the NIH news release, PEDIG is a collaborative network of pediatric ophthalmologists and pediatric optometrists dedicated to conducting multi-center trials on eye disorders that affect children. The trial was funded by the NEI grants EY11751, EY18810 and EY23198.

  1. Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, Kehler LAF, Jordan CO, Raghuram A, Summers AI, Lee KA, Petersen DB, Erzurum SA, Pang Y, Lenhart PD, Ticho BH, Beck RW, Kraker RT, Holmes JM, Cotter SA. Randomized trial of low-dose atropine eyedrops for myopia control. JAMA Ophthal. Published July 13, 2023. doi:10.1001/jamaophthalmol.2023.2855

Related Videos
© 2024 MJH Life Sciences

All rights reserved.